| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/21/2006 | WO2006046951A3 Cell cycle arrest and apoptosis |
| 09/21/2006 | WO2006046734A3 Novel aminopyridine derivatives having selective aurora-a inhibitory effect |
| 09/21/2006 | WO2006043182A3 Screening assays for inhibitors of a staphylococcus aureus siderophore |
| 09/21/2006 | WO2006042240A3 Immunotherapy of autoimmune disorders |
| 09/21/2006 | WO2006029982A3 Treatment of atherosclerosis |
| 09/21/2006 | WO2006023651A3 Extended treatment of multiple sclerosis |
| 09/21/2006 | WO2005067620A8 ANTIBODIES TO MAdCAM |
| 09/21/2006 | WO2005058936A3 Dna sequence, and recombinant production of the grass pollen allergen lol p 4 |
| 09/21/2006 | WO2005055932A3 Therapeutic combinations and methods including irm compounds |
| 09/21/2006 | WO2005019412A3 Mucosal immunization to prevent prion infection |
| 09/21/2006 | US20060212109 Delivery of therapeutic capable agents |
| 09/21/2006 | US20060211639 Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| 09/21/2006 | US20060211602 Use of alanyl aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 09/21/2006 | US20060211150 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance |
| 09/21/2006 | US20060211149 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance |
| 09/21/2006 | US20060211143 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance |
| 09/21/2006 | US20060211142 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance |
| 09/21/2006 | US20060211115 Methods of generating chimeric adenoviruses and uses for such chimeric aden oviruses |
| 09/21/2006 | US20060211107 Protease inhibitor conjugates and antibodies useful in immunoassay |
| 09/21/2006 | US20060211058 Diagnosis and treatment of malignant neoplasms |
| 09/21/2006 | US20060211033 Novel gene |
| 09/21/2006 | US20060211020 Methods for the diagnosis, prognosis and treatment of metabolic syndrome |
| 09/21/2006 | US20060211015 detecting a difference between the levels of an expression product of a cancer associated (CA) gene in a cell in the presence and absence of an anticancer drug candidate; for carcinomas, especially lymphoma carcinomas |
| 09/21/2006 | US20060210974 Compositions and methods for preventing, treating and diagnosing diabetes |
| 09/21/2006 | US20060210965 Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease |
| 09/21/2006 | US20060210960 Method for processing and preserving collagen-based tissues for transplantation |
| 09/21/2006 | US20060210629 Zinc-containing sustained-release composition, its preparation, and method for producing the same |
| 09/21/2006 | US20060210591 Immunization of an individual against carcinomas and the preliminary stages thereof |
| 09/21/2006 | US20060210590 Minor allergen control to increase safety of immunotherapy |
| 09/21/2006 | US20060210589 With botulinum toxin |
| 09/21/2006 | US20060210588 Hiv-peptide-carrier-conjugates |
| 09/21/2006 | US20060210587 Virus-like particles for the induction of autoantibodies |
| 09/21/2006 | US20060210586 Recombination bcg vaccine |
| 09/21/2006 | US20060210585 Method for the production of hiv-1 gag virus-like particles |
| 09/21/2006 | US20060210583 Nucleic acids encoding Sarcocystis neurona antigen and uses thereof |
| 09/21/2006 | US20060210582 Nucleic acids and proteins from streptococcus groups A & B |
| 09/21/2006 | US20060210581 Nucleic acids and proteins from streptococcus groups A & B |
| 09/21/2006 | US20060210580 Nucleic acids and proteins from streptococcus groups A & B |
| 09/21/2006 | US20060210579 Nucleic acids and proteins from streptococcus groups A & B |
| 09/21/2006 | US20060210578 Immunogenic polypeptide isolated from mycobacterium avium subspecies paratuberculosis and uses therof |
| 09/21/2006 | US20060210577 isolated nucleic acid molecule encoding polypeptide as antitumor biodrugs; monoclonal antibody; modulation of chemokine, cytokine expression; transfected host cell; anticarcinogenic agents |
| 09/21/2006 | US20060210576 Method for treating or preventing metastasis of colorectal cancers |
| 09/21/2006 | US20060210575 Cytotoxic protein and utilization thereof |
| 09/21/2006 | US20060210574 Administering immunoglobulins; determination titration of antibodies |
| 09/21/2006 | US20060210573 Containing one or more epitopes recognized by and binding to a BAT monoclonal antibody; diagnosing and treating cancer; cancer vaccines; monoclonal, polyclonal, recombinant, synthetic intact antibody and Fv, F(ab'), F(ab')2 and single chain antibody fragments; polynucleotides |
| 09/21/2006 | US20060210572 Treatment of lymphatic metastatic cancerous lesions |
| 09/21/2006 | US20060210571 Engineering antibodies that bind irreversibly |
| 09/21/2006 | US20060210570 Drug screening; serine protease inhibitors; modulators of HAI-1/1B inhibition of prostasin |
| 09/21/2006 | US20060210569 cell growth inhibitors for pancreatic cancer |
| 09/21/2006 | US20060210568 Methods and compositions for cancer treatment |
| 09/21/2006 | US20060210567 Antibodies against pd-1 and uses therefor |
| 09/21/2006 | US20060210566 Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF) |
| 09/21/2006 | US20060210565 Antagonists of HMG1 for treating inflammatory conditions |
| 09/21/2006 | US20060210564 Novel diabody-type bispecific antibody |
| 09/21/2006 | US20060210563 Administration of anti-cytokine f(ab')2 antibody fragments |
| 09/21/2006 | US20060210562 A soluble immunoglobulin-polypeptide chimera comprising an immunoglobulin having a complementarity determining region 3 (CDR3); endocytic presentation of an immunosuppressive factor for the down regulation of diabetogenic T cells for the treatment of type 1 diabetes |
| 09/21/2006 | US20060210561 Dosages for treatment with anti-EGFR antibodies |
| 09/21/2006 | US20060210560 TNF receptor action modulaton |
| 09/21/2006 | US20060210559 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| 09/21/2006 | US20060210558 Hematopoietic cell selectin ligand polypeptides and methods of use thereof |
| 09/21/2006 | US20060210557 Stabilized liquid polypeptide formulations |
| 09/21/2006 | US20060210556 Novel composition and methods for the treatment of immune disorders |
| 09/21/2006 | US20060210555 Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| 09/21/2006 | US20060210554 Detection of cholesterol ozonation products |
| 09/21/2006 | US20060210552 Compositions and methods for systemic inhibition of cartilage degradation |
| 09/21/2006 | US20060210540 Compositions and methods for enhancing the immunogenicity of antigens |
| 09/21/2006 | US20060210532 Means and methods for the recruitment and identification of stem cells |
| 09/21/2006 | US20060210475 Humanized L243 antibodies |
| 09/21/2006 | US20060210474 Customization of cancer therapy by adminstering modifying antibodies from antigens expressed from cancerous tissue which are cytotoxic to cancer cells while non-toxic to non-cancerous cells; monoclonal antibody antigen binding fragment having identifying characteristics to a cloned deposit |
| 09/21/2006 | CA2601797A1 Mannose immunogens for hiv-1 |
| 09/21/2006 | CA2601677A1 Gene disruptions, compositions and methods relating thereto |
| 09/21/2006 | CA2601676A1 Combination vaccines with whole cell pertussis antigen |
| 09/21/2006 | CA2601518A1 Compositions of hsp60 peptides and viral antigens for vaccination and diagnosis |
| 09/21/2006 | CA2601115A1 Antibodies against candida antigens |
| 09/21/2006 | CA2600877A1 Immunogenic compositions comprising lawsonia intracellularis |
| 09/21/2006 | CA2600714A1 Methods of treating or preventing a disease, disorder or condition associated with a viral infection |
| 09/21/2006 | CA2600696A1 Synthetic anti-candida albicans oligosaccharide based vaccines |
| 09/21/2006 | CA2600568A1 Prophylactic/therapeutic agent for cancer |
| 09/21/2006 | CA2600505A1 Anti-mesothelin antibodies |
| 09/21/2006 | CA2599218A1 Cat allergen conjugates and uses thereof |
| 09/20/2006 | EP1702986A1 BASB013 DNA and proteins from Neisseria meningitidis |
| 09/20/2006 | EP1702985A2 Preferred segments of neural thread protein and methods of using the same |
| 09/20/2006 | EP1702982A1 Method of detecting liver cancer, diagnostic for liver cancer and remedy for cancer |
| 09/20/2006 | EP1702927A1 Attenuated microorganisms for the treatment of infection |
| 09/20/2006 | EP1702625A1 Medicine containing genetically modified antibody against chemokine receptor ccr4 |
| 09/20/2006 | EP1702624A1 Immunotherapeutic stress protein-peptide complexes against cancer |
| 09/20/2006 | EP1702620A1 Immunopotentiator and method of enhancing immunological activity with the same |
| 09/20/2006 | EP1701977A2 Sars coronavirus s proteins and uses thereof |
| 09/20/2006 | EP1701968A2 Immunogenic peptide carrier conjugates and methods of producing same |
| 09/20/2006 | EP1701950A1 Ecstasy haptens and immunogens |
| 09/20/2006 | EP1701949A2 Assay for entactogens |
| 09/20/2006 | EP1701948A1 Assay for entactogens |
| 09/20/2006 | EP1701916A2 Electronic trading data integration and protection system |
| 09/20/2006 | EP1701740A1 Immunologic compounds for prevention, protection, prophylaxis or treatment of immunological disorders, infections and cancer |
| 09/20/2006 | EP1701739A2 Use of agents derived from ceacam1 for the treatment of inflammatory diseases |
| 09/20/2006 | EP1701738A2 Methods for porducing storage stable viruses and immunogenic compositions thereof |
| 09/20/2006 | EP1701737A2 Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo |
| 09/20/2006 | EP1701730A2 Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders |
| 09/20/2006 | EP1701711A1 Nanoparticles for delivery of a pharmacologically active agent |
| 09/20/2006 | EP1432792B1 Histone deacetylase 9 |